MARKET

BMRN

BMRN

Biomarin Pharmaceutical Inc
NASDAQ
93.61
-0.79
-0.84%
After Hours: 93.28 -0.33 -0.35% 18:09 12/05 EST
OPEN
94.23
PREV CLOSE
94.40
HIGH
94.87
LOW
93.24
VOLUME
2.72M
TURNOVER
0
52 WEEK HIGH
117.77
52 WEEK LOW
76.02
MARKET CAP
17.63B
P/E (TTM)
121.79
1D
5D
1M
3M
1Y
5Y
Biomarin Pharmaceutical Inc: Statement of changes in beneficial ownership of securities
Press release · 4h ago
Biomarin Pharmaceutical Inc: Initial statement of beneficial ownership of securities
Press release · 6h ago
Tracking Baker Brothers Portfolio - Q3 2023 Update
Baker brothers' 13f portfolio value increased marginally from $17.28b to $ 17.35b in q3 2023. The largest five stakes in the portfolio are seagen, beigene, incyte, acadia pharma, and biomarin pharma. Stake increases were seen in rhythm pharma, abcellera biologics, and kymera therapeutics.
Seeking Alpha · 1d ago
Weekly Report: what happened at BMRN last week (1127-1201)?
Weekly Report · 1d ago
Biotechs post record gains in November amid improving outlook
Healthcare biotechs post record gains in november amid improving outlook. Gene therapy developers outperformed and pharma giants look for m&a opportunities in the industry. November was the best month for biotechs since november 2020. The spdr s&p biotech etf climbed 14% in november while the healthcare sector rose only 9%.
Seeking Alpha · 2d ago
4 Preeminent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Four preeminent growth stocks you'll regret not buying in the wake of the nasdaq bear market dip. China-based electric vehicle maker nio is the first top-tier growth stock you can buy after the dip. Cybersecurity company okta is another company you should consider buying after the market's dip.
The Motley Fool · 3d ago
Strategic Advancements and Long-Term Gains: Buy Rating on BioMarin Amidst Roctavian’s European Rollout
TipRanks · 4d ago
Analysts Are Bullish on These Healthcare Stocks: UnitedHealth (UNH), Alnylam Pharma (ALNY)
TipRanks · 5d ago
More
About BMRN
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops and commercializes therapies that address the root cause of genetic conditions. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Roctavian (valoctocogene roxaparvovec) and Voxzogo (vosoritide). The Roctavian is an adeno associated virus (AAV5) vector drug development candidate designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. The Company’s clinical development programs include BMN 331, an AAV5 mediated gene therapy for people living with Hereditary Angioedema (HAE) and BMN 255 is a small-molecule therapy that is designed to treat hyperoxaluria in chronic liver disease.

Webull offers Biomarin Pharmaceutical Inc stock information, including NASDAQ: BMRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMRN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BMRN stock methods without spending real money on the virtual paper trading platform.